Clinical trials: Malaria, Plasmodium Falciparum
Plasmodium Infection
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia
This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost-effectiveness of a personal protection package to reduce malaria…
- Trial name
- NCT05117567
- Testing
- Personal protection package
- Volunteers
- 5,868 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria,Falciparum, Malaria in Pregnancy
Plasmodium Falciparum Genomic Intelligence in Mozambique
Mozambique is among the ten countries with the highest burden of malaria worldwide, with an estimated 9.3 million cases in 2018, and constitutes a core target for the World Health Organization (WHO) and the Roll Back Malaria…
- Conditions
- Malaria,Falciparum, Malaria in Pregnancy, Malaria
- Trial name
- GenMoz (NCT05306067)
- Testing
- LDH-based malaria rapid diagnostic test, Malaria rapid diagnostic test
- Where
- Mozambique
- Volunteers
- 21,848 people, healthy volunteers welcome
- Sponsor
- Centro de Investigacao em Saude de Manhica
Malaria
Parasite Clearance and Protection From Infection (PCPI) in Zambia
The Zambia PCPI study will measure the effect of the parasite genotypes associated with SP resistance on parasite clearance and protection from infection when exposed to SP.
- Trial name
- NCT06166498
- Testing
- SP (Macleods Pharmaceuticals Ltd), AS (Guilin Pharmaceuticals)
- Where
- Zambia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria,Falciparum
Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention
In areas of the Sahel sub-region of Africa with intense seasonal malaria transmission, seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SP+AQ) has become the standard-of-care for the…
- Trial name
- DRUMARS (NCT04969185)
- Where
- 2 sites in Burkina Faso
- Volunteers
- 310 people
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria
Pentoxifylline in Children With Malaria
The primary objectives of this study is to identify a safe, tolerable dose of pentoxifylline in children with cerebral malaria and to establish an acceptable pentoxifylline dosage regimen for use in multi center Phase II and…
- Trial name
- NCT00133393
- Testing
- Pentoxifylline
- Where
- Kenya
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Evaluation of Weekly Tafenoquine
This study is a phase 2b, placebo controlled, randomized, blinded study of the efficacy of WR 238605, a new primaquine analog, compared to placebo as chemosuppression of P. falciparum malaria in Nyanza Province, western Kenya.
- Trial name
- NCT02491606
- Testing
- Tafenoquine
- Volunteers
- 249 people
- Sponsor
- U.S. Army Medical Research and Development Command
Weight Loss, Weight Gain
Effect of Ready to Use Therapeutic Food (RUTF) Supplement After an Episode of Malaria Falciparum on Weight
The primary objective of this study is to determine to what extent provision with RUTF will promote catch up growth in children following an acute uncomplicated episode of P. falciparum malaria.
- Conditions
- Weight Loss, Weight Gain, Convalescence, Malaria
- Trial name
- NCT00819858
- Testing
- RUTF (Plumpynut®)
- Where
- Republic of the Congo
- Volunteers
- 180 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Severe Malaria
Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
Currently, 16 African countries include the use of pre-referral rectal artesunate (RAS) in their treatment policies. However, guidelines for RAS use vary widely across countries and inappropriate use of RAS as a monotherapy and…
- Trial name
- Caramal DRM (NCT04037332)
- Testing
- Blood sample (combined with malaria RDT) followed by gentoyping analysis
- Where
- 7 sites in Democratic Republic of the Congo, Nigeria and 1 more
- Volunteers
- 916 people
- Sponsor
- Swiss Tropical & Public Health Institute
Malaria
Intermittent Preventive Treatment in Infant in Mali
Studies have shown that Intermittent preventive treatment in infants (IPTi) with Sulfadoxine-pyrimethamine (SP)reduced the incidence of clinical malaria and anemia without modifying infants' serological response to EPI vaccines.
- Trial name
- NCT00766662
- Testing
- Sulfadoxine pyrimethamine
- Where
- Mali
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Bamako
Plasmodium Falciparum Malaria
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
The objective of this study was to evaluate the safety of a candidate malaria vaccine (PfAMA-1) at 3 doses given at monthly intervals of 2 different dosages of AMA-1 (10 μg or 50 μg ) adjuvanted either with alum hydroxide or…
- Trial name
- NCT00730782
- Testing
- PfAMA-1-FVO[25-545]
- Where
- 2 sites in Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- European Vaccine Initiative
Malaria, Falciparum
Mass-Drug Administration to Reduce Malaria Transmission
In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'.
- Trial name
- MDATRANS (NCT00509015)
- Testing
- Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Artesunate (day 1,2,3: 4 mg/kg), Primaquine-base (day 3: 0.75 mg/kg)
- Where
- Tanzania
- Volunteers
- 6,000 people
- Sponsor
- Radboud University Medical Center
Asymptomatic P.Falciparum Malaria
Artemisia Annua Infusion for the Treatment of Asymptomatic Plasmodium Falciparum Infection
The goal of this clinical trial is to determine whether Artemisia annua dried leaves, used as an infusion, can treat individuals with malaria parasites but no symptoms.
- Trial name
- ART-CT001 (NCT07819825)
- Testing
- Artemisia Annua Leaf, Centaurii herba
- Where
- Gabon
- Volunteers
- 20 people
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Plasmodium Falciparum Malaria
Hyperphenylalaninemia in Cerebral Malaria
The purpose of this study is to see if children, who develop coma from malaria, are not making enough of a vitamin-like chemical, tetrahydrobiopterin (BH4), which is required for the brain to function normally.
- Trial name
- NCT00338520
- Where
- Tanzania
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- University of Utah
Malaria
Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
Malaria, a disease caused by the parasite Plasmodium, is one of the world's major infectious diseases. With approximately 627.000 deaths a year, it is both a chief cause of morbidity and mortality as well as a significant…
- Trial name
- BMGF2b (NCT02098590)
- Testing
- CPS-immunization, malaria challenge infection, P. falciparum NF135.C10, malaria challenge infection, P. falciparum NF166.C8
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria, Falciparum
Study of the Impact of Intermittent Preventive Treatment in Schools on Malaria, Anaemia and Education.
This study seeks to establish whether intermittent preventive treatment (IPT) can reduce malaria among school-going children and its consequent impact on school performance.
- Trial name
- NCT00142246
- Testing
- Intermittent preventive treatment (SP and amodiaquine)
- Where
- Kenya
- Volunteers
- 6,758 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria,Falciparum
Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54
Objectives: Primary: To characterize the infectivity of the new lot of Plasmodium falciparum strain 3D7 within the standard WRAIR CHMI model as compared to the current lot (historical data) Secondary: To assess safety of the new…
- Trial name
- NCT03882528
- Testing
- Plasmodium falciparum malaria parasite
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Uncomplicated P. Falciparum Malaria
SPK Study in Afghanistan
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine. In 2003 the high failure rate of chloroquine against falciparum malaria led the national malaria…
- Trial name
- NCT01707199
- Testing
- Artesunate + Sulphadoxine-pyrimethamine
- Where
- Afghanistan
- Volunteers
- 83 people
- Sponsor
- University of Oxford
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235033)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 3 sites in Côte d’Ivoire, Gabon and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Malaria, Falciparum
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults
This is an open-label, single-centre Phase I P. falciparum blood-stage vaccine trial to assess the safety and immunogenicity and efficacy of the candidate malaria vaccines R78C and RH5.1 formulated in adjuvant Matrix-M
- Trial name
- NCT05385471
- Testing
- Matrix M with R78C and/or RH5.1
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
Coadministration of GA2 Sporozoites With Adjuvants
This study will assess the coadministration of genetically attenuated Plasmodium falciparum ∆mei2 (GA2) sporozoites with adjuvants (BCG and YF-17D vaccination and imiquimod cream).
- Trial name
- CoGA (NCT05468606)
- Testing
- GA2, BCG, YF-17D (fractional ID dose)
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center